Xeltis’ Aortic Valve preclinical results shared at TCT 2017
The latest study results from Xeltis’ preclinical aortic valve program have been presented by Professor Christian Spaulding (European Hospital Georges Pompidou, Paris – France) during a dedicated satellite session on ETR at TCT 2017. The data showed promising results with good hemodynamic performance and fully functional valves in vivo 12 months after implantation.
The satellite session, co-chaired by Dr Neil Moat, Royal Brompton Hospital, London and Dr Gregory Fontana, Cardiovascular Institute, California, provided an overview of the principles, potential and development status of restorative heart valve therapy through Endogenous Tissue Restoration (ETR). ‘Restorative Heart Valves: Tomorrow’s World’ also included presentations from Professor Virmani (CVPath Institute), Professor Martin B. Leon (Columbia University Medical Center), and Xeltis’ CTO and co-founder Martijn Cox.
Transcatheter Cardiovascular Therapeutics (TCT) is a leading medical congress organized by the Cardiovascular Research Foundation (CRF), taking place October 29-November 2, 2017 at the Colorado Convention Center, Denver, Colorado. TCT specializes in interventional cardiovascular medicine. It serves to showcase the latest advances in current therapies and clinical research.